Cargando…

Safety Analysis of Bevacizumab in Ovarian Cancer Patients

Bevacizumab (BEV) is beneficial for ovarian cancer patients, but the real world’s patient settings differ from those in clinical trials. This study tries to illustrate adverse events in the Taiwanese population. Patients with epithelial ovarian cancer treated with BEV at Kaohsiung Chang Gung Memoria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yingwen, Lin, Hao, Ou, Yuche, Fu, Hungchun, Tsai, Chingchou, Chien, Chanchao Chang, Wu, Chenhsuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003828/ https://www.ncbi.nlm.nih.gov/pubmed/36902852 http://dx.doi.org/10.3390/jcm12052065

Ejemplares similares

Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011)

Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
por: Hung, Jo-Ni, et al.
Publicado: (2022)

Critical appraisal of bevacizumab in the treatment of ovarian cancer
por: Yoshida, Hiroyuki, et al.
Publicado: (2015)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

Bevacizumab as adjunct to chemotherapy for chemoresistant ovarian cancer
por: Hamilton, Gerhard
Publicado: (2020)

The efficacy and safety of irinotecan ± bevacizumab compared with oxaliplatin ± bevacizumab for metastatic colorectal cancer: A meta-analysis
por: Dai, Jiali, et al.
Publicado: (2019)

Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials
por: Wu, Yu Shen, et al.
Publicado: (2016)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Association of bevacizumab and stroke in ovarian cancer: a systematic review and meta-analysis
por: Song, Li, et al.
Publicado: (2023)

The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab
por: Kuk, Anna, et al.
Publicado: (2017)

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
por: Lallemand, Christophe, et al.
Publicado: (2020)

The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects
por: Mao, Chih-Lin, et al.
Publicado: (2022)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
por: Pujade-Lauraine, Eric
Publicado: (2013)

Recurrent colon perforation after discontinuation of bevacizumab for ovarian cancer
por: Nonaka, Michiko, et al.
Publicado: (2018)

Analysis of the activity and safety of weekly low‐dose bevacizumab‐based regimens in heavily pretreated patients with metastatic breast cancer
por: Zhai, Xiaoyu, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
por: Neyt, Mattias, et al.
Publicado: (2018)

Bevacizumab combined with chemotherapy for ovarian cancer: A protocol for systematic review and meta-analysis
por: Liao, Ting, et al.
Publicado: (2021)

Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease
por: Herrera-Gómez, Ruth Gabriela, et al.
Publicado: (2022)

α-Mangostin and Apigenin Induced Cell Cycle Arrest and Programmed Cell Death in SKOV-3 Ovarian Cancer Cells
por: Ittiudomrak, Teeranai, et al.
Publicado: (2019)

Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
por: Sekine, Masayuki, et al.
Publicado: (2021)

Effects of Icodextrin Solution (Adept(®)) on Ovarian Cancer Cell Proliferation in an In Vitro Model
por: Chen, Wen-Hsin, et al.
Publicado: (2022)

Severe progressive dermatomyositis in a patient with metastatic ovarian cancer using bevacizumab
por: Menteşoğlu, Dilek, et al.
Publicado: (2022)

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
por: McClung, E Clair, et al.
Publicado: (2016)

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
por: Mahner, Sven, et al.
Publicado: (2015)

First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
por: Marchetti, Claudia, et al.
Publicado: (2019)

Bevacizumab in ovarian cancer: A critical review of phase III studies
por: Rossi, Luigi, et al.
Publicado: (2016)

Spontaneous massive duodenal perforation after ovarian cancer treatment with bevacizumab
por: Karanikas, Michael, et al.
Publicado: (2020)

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
por: Kaparelou, Maria, et al.
Publicado: (2022)

Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis
por: Zhou, Mingyi, et al.
Publicado: (2013)

Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis
por: Ma, Hongbo, et al.
Publicado: (2019)

Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer
por: Ercelep, Özlem, et al.
Publicado: (2020)

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer
por: Wu, Qian, et al.
Publicado: (2013)

Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK
por: Plummer, Chris, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c8ti7c94j0fng9ohs6124h051v